bioRxiv Science⌕ Search

Biology subjects

Lenhof, H.-P.

Publications and source records attributed to Lenhof, H.-P..

3 recordsLinked to original sources

How to Predict Effective Drug Combinations - Moving beyond Synergy Scores

To improve our understanding of multi-drug therapies, cancer cell line panels screened with drug combinations are frequently studied using machine learning (ML). ML models trained on such data typically focus on predicting synergy scores, which support drug development and repurposing efforts but have limitations when deriving personalized treatment recommendations. To simulate a more realistic personalized treatment scenario, we pioneer ML models that predict the relative growth inhibition (instead of synergy scores), and that can be applied to previously unseen cell lines. Our approach is highly flexible: it enables the reconstruction of dose-response curves and matrices, as well as various measures of drug sensitivity (and synergy) from model predictions, which can finally even be used to derive cell line-specific prioritizations of both mono- and combination therapies.

bioinformatics↗

Cas9-Mediated Knockout of Ndrg2 Enhances the Regenerative Potential of Dendritic Cells for Wound Healing

Chronic wounds impose a significant healthcare burden to a broad patient population. Cell based therapies, while having shown benefits for the treatment of chronic wounds, have not achieved widespread adoption into clinical practice. Here, we developed a novel CRISPR/Cas9 approach to precisely edit dendritic cells (DCs) to enhance their therapeutic potential for healing chronic wounds. Using single-cell RNA sequencing (scRNA-seq) of tolerogenic DCs, we discover N-myc downregulated gene 2 (Ndrg2), which marks a specific population of DC progenitors, as a promising target for CRISPR knockout (KO). Ndrg2-KO alters the transcriptomic profile of DCs and preserves an immature cell state with a strong, pro-angiogenic and regenerative capacity. We then incorporated our CRISPR-based cell engineering within a hydrogel technology for in vivo cell delivery and developed a highly effective translational approach for DC based immunotherapy that accelerated healing of full-thickness wounds in both non-diabetic and diabetic mouse models. These findings could open the door to future clinical trials using safe gene editing in DCs for treating various types of chronic wounds.

cell biology↗

Machine learning to detect Alzheimer’s disease from circulating non-coding RNAs

BackgroundTo develop therapeutics for Alzheimers disease, early detection of patients awakes new hope. Circulating small non-coding RNAs are among the prominent candidates for a blood-based diagnosis, requiring however growing cohort sizes.\n\nMethodsWe determined abundance levels of 21 known circulating microRNAs in 465 individuals encompassing Alzheimers patients and controls recruited in US and Germany. We computed models to assess the relation between microRNA-expression and phenotypes, gender, age and disease severity (Mini-Mental State Examination MMSE).\n\nResults20 of 21 miRNAs were consistently dys-regulated in the US and Germany. 18 were significantly correlated to neurodegeneration (adjusted p<0.05) with highest significance for miR-532-5p (adjusted p=4.8x10-30). Ten miRNAs were significantly correlated with MMSE, in particular miR-26a/26b-5p (adjusted p=0.0002). Machine learning models reached an AUC value of 87.6% in differentiating AD patients from controls.\n\nConclusionsOur data provide strong evidence for the relevance of circulating non-coding RNAs to detect Alzheimers from a blood sample.

bioinformatics↗